- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
The science of direct-acting antiviral and host-targeted agent therapy;
Pawlotsky JM; Antiviral Therapy 17 (6 Pt B), 1109-17 (2012)
直接作用抗病毒药物的科学
Direct-acting antiviral drugs targeting two major steps of the HCV life cycle, polyprotein processing and replication, and cyclophilin inhibitors, that target a host cell protein required to interact with the replication complex, have reached clinical development. In order to achieve a sustained virological response, that is, a cure of the HCV infection, it is necessary to shut down virus production, to maintain viral inhibition throughout treatment and to induce a significant, slower second-phase decline in HCV RNA levels that leads to definitive clearance of infected cells. Recent findings suggest that the interferon era is coming to an end in hepatitis C therapy and HCV infection can be cured by all-oral interferon-free treatment regimens within 12 to 24 weeks. Further results are awaited that will allow the establishment of an ideal first-line all-oral, interferon-free treatment regimen for patients with chronic HCV infection
直接作用的抗病毒药物,针对丙型肝炎病毒的生命周期,聚处理和复制的两个主要步骤,和亲环素抑制剂,该目标宿主细胞的蛋白质交互所需的复制复合物,达到临床试验阶段。为了实现持续的病毒学反应,即,固化的HCV感染,是必要关闭病毒生产的,以保持在整个治疗的病毒抑制和诱导显着的,速度较慢的第二阶段的HCV RNA水平下降导致最终清除感染的细胞。最近的研究结果表明,干扰素的时代即将结束C型肝炎的治疗和丙型肝炎病毒感染是可以治愈的,所有在12至24周的口服干扰素治疗方案。正在等待进一步的结果,将允许建立一个理想的第一线口服,
无干扰素治疗慢性丙型肝炎病毒感染的治疗方案为患者。
|
|